Quantcast

Industry news that matters to you.  Learn more

Archives for October 2010

New Clinical Data for Septin9 Colorectal Cancer Blood Test Presented at UEGW

Epigenomics AG, the cancer diagnostics company, announced that new data obtained in a clinical study with the Company’s proprietary Septin9 biomarker for the blood-based detection of colorectal cancer were presented yesterday at the 18th United European Gastroenterology Week (UEGW) in Barcelona, Spain.

Pacific Biosciences Looks to Raise $200M through $16 per Share IPO

Next-gen sequencing firm Pacific Biosciences has priced its initial public offering (IPO) of 12,500,000 shares of common stock at $16 per share. The firm, which is going public today, has in addition offered its underwriters a 30-day option to purchase up to 1,875,000 shares at the IPO price, to cover any overallotments.

Karmanos Cancer Institute Uses Definiens Tissue Studio for Biomarker Development

Definiens, the number one Health Image Intelligence company, today announced that the Barbara Ann Karmanos Cancer Institute in Detroit is using Definiens image analysis software in a new approach to cancer diagnosis and biomarker development. The Karmanos Cancer Institute is applying Definiens Tissue Studio 2.0TM, the newest version of the company’s leading image analysis software for digital pathology, to automate tissue section and microarray analysis. Led by Gerold Bepler, M.D., Ph.D., president and CEO of the Karmanos Cancer Institute, the research team will replace tedious manual analysis processes with automated image analysis to more reliably develop biomarkers that facilitate patient stratification models for personalized medicine applications.

New Multiplex Tissue Biomarker Service Launched to Advance Companion Diagnostics Development in a Regulated Environment

Flagship Biosciences announced today the launch of a new tissue biomarker multiplexing analytical tool for tumors and other tissues. The patent pending technique is based on advanced image registration approaches in radiology fields and applied to consecutive histology sections. The novel technology approach will be presented at Pathology Visions 2010 in San Diego. Flagship is currently offering the multiplexing technology as part of their digital pathology services.

Neogenix Oncology to Present Data on the Detection of Colorectal and Pancreatic Cancer at ASCO’s 2010 Annual Meeting on Molecular Makers in Cancer

Neogenix Oncology, Inc. announced today that it will present data from its new serum biomarker ELISA utilizing its NPC-1C antibody for patients with colorectal and pancreatic cancers. Results from the study will be presented at the American Society of Clinical Oncology (ASCO)-NCI-EORTC Annual Meeting on Molecular Makers in Cancer, to be held in Hollywood, Florida from October 18-20, 2010.